Kemi Biopharmaceuticals

Chimigen Bio's core technology is its proprietary SynNeogen® immunotherapy platform. This platform is designed to initiate de novo T-cell immunity, a challenge for many current treatments, particularly in immune-cold tumors and chronic viral infections. The technology mimics the body's natural antigen processing and presentation to induce antigen-specific immune responses. The company's business model centers on developing and commercializing a pipeline of therapeutic vaccines and other immunotherapies derived from this platform. It generates revenue through the development of these therapies and is open to partnerships, including licensing, asset acquisition, and co-development.

The company's product pipeline includes candidates for cancer and infectious diseases, with a focus on unmet clinical needs in prostate cancer and chronic hepatitis B. Core products in development include SN3001, a therapeutic vaccine for prostate cancer, and SN2001, an immunotherapy vaccine for chronic hepatitis B. In May 2025, SN2001 received Investigational New Drug (IND) clearance from the U.S. FDA. Chimigen has secured significant funding to advance its clinical programs, including a Series A round of $14.1 million in September 2022 and a Pre-A funding of CNY 170 million in July 2025. Key investors include Puhua Capital, SDIC Venture Capital, and Casstar Capital.